• Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

    A CheckMate 9LA trial update shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced NSCLC.

  • Global Outbreak Update: First avian influenza A(H10N3) human infection in Zhenjiang, China

    On 31 May 2021 China's National Health Commission notified WHO of one confirmed case in Zhenjiang City, Jiangsu Province. The patient is in a stable condition.

  • Metastatic castration-resistant prostate cancer: VISION trial meets its endpoints

    Addition of 177Lu-PSMA-617 therapy to standard of care for mCRPC patients significantly improves survival, according to the phase-3 VISION trial results.

  • PARP7 inhibitor shows promising results in first-in-human trial

    RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumour immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial.

  • Rituximab or JAKi therapies in rheumatoid arthritis increase the risk of severe COVID-19

    Severe COVID-19 outcomes risk in RA patients is 4 times higher for rituximab, and 2 times higher for JAK inhibitor users compared to TNF inhibitor users. This was not found for abatacept or IL-6-inhibiting DMARDs.

  • Efficacy and safety of secukinumab in juvenile idiopathic arthritis

    Secukinumab significantly increased the time leading to, and reduced the number of flares in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) when compared with placebo.

  • Molecular tumour profiling: Significant impact on solid tumours in young patients

    First results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling for the diagnosis and treatment of solid tumours in young patients.

  • Mavrilimumab outperforms placebo in severe COVID-19

    In patients with severe COVID-19 pneumonia and hyper-inflammation, mavrilimumab was associated with decreased mechanical ventilation and death compared with placebo.

  • PET/CT is a reliable outcome measure of disease activity in large-vessel vasculitis

    PET/CT showed a discriminating value in measuring disease activity in large-vessel vasculitis (LVV). This finding was consistent in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) subgroups.

  • Ultrasound: promising biomarker for treatment response in very early RA

    In patients with VERA on methotrexate + tocilizumab combination therapy, ultrasound imaging was able to detect treatment response in an earlier stage than clinical examination scores.

  • Remote management of RA is a feasible alternative for outpatient follow-up

    During the COVID-19 pandemic, rheumatoid arthritis remote management is a feasible alternative for routine outpatient follow-up according to a prospective, longitudinal real-world study of UK patients.

  • Breast cancer: Effects on social and professional life underestimated?

    Breast cancer has a greater impact on the quality of life and work of those affected than previously assumed,as found by an ongoing study focused on women with breast cancer during therapy.

  • Prognostic factors for minimal disease activity in early psoriatic arthritis revealed

    MDA following a treat-to-target strategy in early PsA can be predicted by a combination of factors, including Tender Joint Count, PGA of disease activity, pain, and the absence of enthesitis and dactylitis.

  • Passive smoking associated with an increased risk of rheumatoid arthritis

    Exposure to passive smoking in childhood and/or adulthood is associated with RA increased risk, according to the large prospective E3N-EPIC cohort study of French women.

  • Prostate cancer: Better prognosis with a triple therapy

    In a recent study, a significant improvement in PFS probability was observed in the treatment of patients with advanced castration-resistant prostate cancer through the use of ribociclib, docetaxel and prednisone.

  • No effect of FMT in active peripheral psoriatic arthritis

    Fecal microbiota transplantation (FMT) as an add-on therapy to methotrexate was inferior to treat active PsA, compared to sham in a proof-of-concept, randomized, placebo-controlled FLORA trial.

  • Ultrasound for microimplants

    Researchers are developing a new generation of microimplants which can be charged completely wirelessly using ultrasound waves.

  • Severe COVID-19 course with cancer: Impaired immune response may be the cause

    Patients with cancer who are infected with the coronavirus have an increased risk of severe COVID-19 disease.

  • Air pollution predicts decreased response to biological treatment in rheumatic diseases

    According to a case-crossover study, a poor response to bDMARDs in CIA patients is associated with air pollution; adding to further evidence to its relevance as a factor in rheumatic diseases.

  • Interview: Prof. Seng Gee Lim and the Singapore Hepatology Conference 2021

    esanum, as SHC 2021 digital media partner, chats with Conference President Prof. Seng Gee Lim about the virtual international conference on the prevention and treatment of liver diseases.

  • 46 |
  • 47 |
  • 48 |
  • 49 |
  • 50 |
  • 51 |
  • 52 |
  • 53 |
  • 54 |
  • 55 |
  • 56 |